Clinical efficacy and safety of rituximab in lupus nephritis

References

• EmamikiaSGentlineCChatzidionysiouKArnaudLvan VollenhovenRRelationship between glucocorticoid dose and adverse events in systemic lupus erythematosus: data from a randomized clinical trialScand J Rheumatol201847213114028862513
   PubMed Web of Science ®Google Scholar
• LiuYCuiYZhangXEffects of salvianolate on bone metabolism in glucocorticoid-treated lupus-prone b6.Mrl-fas (lpr)/j miceDrug Des Devel Ther20161025352546
   PubMed Web of Science ®Google Scholar
• HeY-YYanYZhangH-FMethyl salicylate 2-O-β-d-lactoside alleviates the pathological progression of pristane-induced systemic lupus erythematosus-like disease in mice via suppression of inflammatory response and signal transductionDrug Des Devel Ther20161031833196
   PubMed Web of Science ®Google Scholar
• GadakchiLHajialiloMNakhjavaniM-REfficacy and safety of mycophenolate mofetil versus intravenous pulse cyclophosphamide as induction therapy in proliferative lupus nephritisIran J Kidney Dis201812528829230367020
   PubMed Web of Science ®Google Scholar
• JorgeAWallaceZSZhangYAll-Cause and Cause-Specific Mortality Trends of End-Stage Renal Disease Due to Lupus Nephritis from 1995 to 2014Hoboken, NJArthritis & Rheumatology2018
   Google Scholar
• HahnBHMcmahonMAWilkinsonAAmerican College of rheumatology guidelines for screening, treatment, and management of lupus nephritisArthritis Care Res2012646797808
   PubMed Web of Science ®Google Scholar
• ParkD-JChoiS-EXuHChronicity index, especially glomerular sclerosis, is the most powerful predictor of renal response following immunosuppressive treatment in patients with lupus nephritisInt J Rheum Dis201821245846729314776
   PubMed Web of Science ®Google Scholar
• HuangWQuachTDDascaluCBelimumab promotes negative selection of activated autoreactive B cells in systemic lupus erythematosus patientsJCI Insight2018317e122525
   PubMed Web of Science ®Google Scholar
• SchioppoTIngegnoliFCurrent perspective on rituximab in rheumatic diseasesDrug Des Devel Ther20171128912904
   PubMed Web of Science ®Google Scholar
• BordronABagaceanCMohrAResistance to complement activation, cell membrane hypersialylation and relapses in chronic lymphocytic leukemia patients treated with rituximab and chemotherapyOncotarget2018960315903160530167081
   PubMedGoogle Scholar
• DiószegiÁTarrTNagy-VinczeMMicrothrombotic renal involvement in an SLE patient with concomitant catastrophic antiphospholipid syndrome: the beneficial effect of rituximab treatmentLupus20182791552155829635999
   PubMed Web of Science ®Google Scholar
• ChavarotNVerhelstDPardonARituximab alone as induction therapy for membranous lupus nephritis: a multicenter retrospective studyMedicine20179627e742928682905
   PubMed Web of Science ®Google Scholar
• RovinBHFurieRLatinisKEfficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus nephritis assessment with rituximab studyArthritis Rheum20126441215122622231479
   PubMed Web of Science ®Google Scholar
• DersimonianRLairdNMeta-analysis in clinical trialsControl Clin Trials1986731771883802833
   PubMedGoogle Scholar
• SfikakisPPBoletisJNLionakiSRemission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trialArthritis Rheum200552250151315693003
   PubMed Web of Science ®Google Scholar
• Vigna-PerezMHernández-CastroBParedes-SaharopulosOClinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot studyArthritis Res Ther200683R8316677395
   PubMed Web of Science ®Google Scholar
• GunnarssonISundelinBJónsdóttirTHistopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritisArthritis Rheum20075641263127217393458
   PubMed Web of Science ®Google Scholar
• LindholmCBörjesson-AspKZendjanchiKLongterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosusJ Rheumatol200835582683318398943
   PubMed Web of Science ®Google Scholar
• BoletisJNMarinakiSSkaliotiCRituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective studyNephrol Dial Transplant20092472157216019179411
   PubMed Web of Science ®Google Scholar
• LiEKTamLSZhuTYIs combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?Rheumatology200948889289819478041
   PubMed Web of Science ®Google Scholar
• MelanderCSalleeMTrollietPRituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcomeClin J Am Soc Nephrol20094357958719261822
   PubMed Web of Science ®Google Scholar
• PepperRGriffithMKirwanCRituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroidsNephrol Dial Transplant200924123717372319617257
   PubMed Web of Science ®Google Scholar
• CatapanoFChaudhryANJonesRBLong-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosusNephrol Dial Transplant201025113586359220466686
   PubMed Web of Science ®Google Scholar
• Garcia-CarrascoMMendoza-PintoCSandoval-CruzMAnti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patientsLupus201019221321919965944
   PubMed Web of Science ®Google Scholar
• Ramos-CasalsMGarcía-HernándezFJde RamónEOff-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseasesClin Exp Rheumatol201028446847620525449
   PubMed Web of Science ®Google Scholar
• CondonMBAshbyDPepperRJProspective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroidsAnn Rheum Dis20137281280128623740227
   PubMed Web of Science ®Google Scholar
• DaviesRJSangleSRJordanNPRituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritisLupus201322657458223632989
   PubMed Web of Science ®Google Scholar
• JónsdóttirTZickertASundelinBLong-term follow-up in lupus nephritis patients treated with rituximab – clinical and histopathological responseRheumatology201352584785523287364
   PubMed Web of Science ®Google Scholar
• TsanyanMESolovievSKRadenska-LopovokSGClinical and morphological improvement of lupus nephritis treated with rituximabFolia Med2014564245252
   Google Scholar
• ContisAVanquaethemHTruchetetM-EAnalysis of the effectiveness and safety of rituximab in patients with refractory lupus nephritis: a chart reviewClin Rheumatol201635251752226762196
   PubMed Web of Science ®Google Scholar
• KotagiriPMartinAHughesPBeckerGNichollsKSingle-dose rituximab in refractory lupus nephritisIntern Med J201646889990127242250
   PubMed Web of Science ®Google Scholar
• HoganJGodronABaudouinVCombination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritisPediatr Nephrol201833111111628780657
   PubMed Web of Science ®Google Scholar
• MoroniGRaffiottaFTrezziBRituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational studyRheumatology20145391570157724505125
   PubMed Web of Science ®Google Scholar
• ZhangJZhaoZHuXEffect of rituximab on serum levels of anti-C1q and antineutrophil cytoplasmic autoantibodies in refractory severe lupus nephritisCell Biochem Biophys201572119720125490907
   PubMed Web of Science ®Google Scholar
• BasuBRoyBBabuBGEfficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritisPediatr Nephrol20173261013102128191596
   PubMed Web of Science ®Google Scholar
• GoswamiRPSircarGSitHGhoshAGhoshPCyclophosphamide versus mycophenolate versus rituximab in lupus nephritis remission induction: a historical head-to-head comparative studyJ Clin Rheumatol2019251283529561474
   PubMed Web of Science ®Google Scholar
• ZhouYXiaoLTangSAnnexin A2 and FTH1 are potential biomarkers for lupus nephritisExp Ther Med20181653766377630344652
   PubMed Web of Science ®Google Scholar
• SedhainAHadaRAgrawalRKBhattaraiGRBaralALow dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trialBMC Nephrol201819117529996800
   PubMed Web of Science ®Google Scholar
• ClarkMRTrotterKChangAThe pathogenesis and therapeutic implications of tubulointerstitial inflammation in human lupus nephritisSemin Nephrol201535545546426573548
   PubMed Web of Science ®Google Scholar
• Gomez MendezLMCascinoMDGargJPeripheral blood B cell depletion after rituximab and complete response in lupus nephritisClin J Am Soc Nephrol20181310 CJN.01070118– CJN.01071509
   PubMed Web of Science ®Google Scholar
• Díaz-LagaresCCrocaSSangleSEfficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohortsAutoimmun Rev201211535736422032879
   PubMed Web of Science ®Google Scholar
• AlshaikiFObaidEAlmuallimAOutcomes of rituximab therapy in refractory lupus: a meta-analysisEur J Rheumatol20185211812630185361
   PubMed Web of Science ®Google Scholar
• AhujaATeichmannLLWangHAn acquired defect in IgG-dependent phagocytosis explains the impairment in antibody-mediated cellular depletion in lupusJ Immunol201118773888389421873531
   PubMed Web of Science ®Google Scholar
• Md YusofMYShawDEl-SherbinyYMPredicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosusAnn Rheum Dis201776111829183628684557
   PubMed Web of Science ®Google Scholar
• RoccatelloDSciasciaSBaldovinoSA 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment-Clinical response compared to literature and immunological re-assessmentAutoimmun Rev201514121123113026244817
   PubMed Web of Science ®Google Scholar
• SjӧwallCBentowCAureMAMahlerMTwo-Parametric immunological score development for assessing renal involvement and disease activity in systemic lupus erythematosusJ Immunol Res20182018219
   Web of Science ®Google Scholar
• FulgeriCCarpioJDArdilesLKidney injury in systemic lupus erythematosus: lack of correlation between clinical and histological dataNefrologia201838438639330032856
   PubMed Web of Science ®Google Scholar
• ShidhamGAyoubIBirminghamDLimited reliability of the spot urine Protein/Creatinine ratio in the longitudinal evaluation of patients with lupus nephritisKidney Int Rep2018351057106330197972
   PubMed Web of Science ®Google Scholar